Chronic Lymphocytic Leukemia

New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL

2023-09-23

  • Study

    Phase II, open label, multicenter (CLL-2-Give)
    Previously untreated patients with high-risk chronic lymphocytic leukemia (CLL) with del(17p) and/or TP53 mutation
    GIVe (Venetoclax + İbrutinib + Obinutuzumab) (n=41)

  • Efficacy

    CR at cycle 15: 58.5% [42.1-73.7]
    36 mos PFS: 79.9%
    36 mos OS: 92.6%

  • Safety

    Grade3 Aes: Neutropenia (48.8%), infections (19.5%), Atrial fibrillation (2.4%), hypertension (4.9%).


    • Blood (2023) 142 (11): 961–972

    Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

    http://doi.org/10.1182/blood.2023020013

    Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023